SCHEMBL3389394

SCHEMBL3389394

Nc1cccc(Nc2ncc(C3CC3)c(NCCCNC(=O)c3cccs3)n2)c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 17/20 0.83
PDPK1 O15530 4/20 0.62
ULK1 O75385 5/20 0.58
ULK2 Q8IYT8 5/20 0.58
IKBKE Q14164 3/20 0.58
NUAK1 O60285 2/20 0.58
PDK1 Q15118 2/20 0.58
CGAS Q8N884 1/20 0.58
MARK3 P27448 3/20 0.54
MARK4 Q96L34 2/20 0.54
STK17A Q9UEE5 2/20 0.54
PRKAA2 P54646 1/20 0.51
SIK1 P57059 1/20 0.51
PRKAA1 Q13131 1/20 0.51
MELK Q14680 1/20 0.51
MARK2 Q7KZI7 1/20 0.51
NUAK2 Q9H093 1/20 0.51
SIK2 Q9H0K1 1/20 0.51
MARK1 Q9P0L2 1/20 0.51
SIK3 Q9Y2K2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13431790 0.92 TBK1 (0.83) TBK1PDPK1ULK1ULK2IKBKE
SCHEMBL3389382 0.91 TBK1 (0.80) TBK1PDPK1ULK1ULK2IKBKE
SCHEMBL13431784 0.91 TBK1 (1.00) TBK1PDPK1ULK1ULK2IKBKE
SCHEMBL13431811 0.91 TBK1 (0.82) TBK1PDPK1ULK1ULK2IKBKE
SCHEMBL13431812 0.91 TBK1 (0.81) TBK1PDPK1ULK1ULK2IKBKE
SCHEMBL13431793 0.90 TBK1 (0.81) TBK1PDPK1ULK1ULK2IKBKE
SCHEMBL13431807 0.90 TBK1 (0.80) TBK1PDPK1ULK1ULK2IKBKE
SCHEMBL13431788 0.89 TBK1 (0.81) TBK1PDPK1ULK1ULK2IKBKE
SCHEMBL13431801 0.89 TBK1 (0.79) TBK1PDPK1ULK1ULK2IKBKE
SCHEMBL13431819 0.89 TBK1 (0.79) TBK1PDPK1ULK1ULK2IKBKE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 US disclosed
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 US disclosed
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 US disclosed
WO-2009122180-A1 PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES MEDICAL RESEARCH COUNCIL (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056524-A1 Compound NR3C2, NR3C1, NR2E3 TBK1 2898/4885PDPK1 2468/4885ULK1 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.